A mini review of antiviral compounds against dengue virus

Abstract

This manuscript presents a comprehensive review of current research and potential future prospects in the development of
antiviral compounds against the dengue virus (DENV). Despite ongoing research, dengue fever (DF), caused by DENV, remains a significant global public health problem, with no specific antiviral treatment available. In this study, an exhaustive survey of literature to provide a detailed overview of the promising antiviral agents, their modes of action, efficacy, and current status in clinical trials. Key areas of focus include small molecule inhibitors that target various stages of the DENV lifecycle, host-targeted agents, and broad-spectrum antivirals. In addition, the challenges associated with the development of effective antivirals, such as the viral diversity of four DENV serotypes and the phenomenon of antibody-dependent enhancement (ADE). This review also explores potential strategies for overcoming these challenges and emphasizes the need for a combination of approaches for effective therapy. In this age of rapidly emerging and re-emerging infectious diseases, a deep understanding of DENV biology and the development of effective antiviral compounds is essential. Our analysis will guide future studies and contribute to ongoing efforts to combat dengue fever.